First Line Treatment Choice for Chronic Myelogenous Leukemia: Modeling of Clinical and Economic Factors

VA Shuvaev, KM Abdulkadyrov, IS Martynkevich, MS Fominykh

Russian Scientific Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024

For correspondence: Vasilii Anatol’evich Shuvaev, PhD, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024; Tel.: +7(921)636-54-72; e-mail:

For citation: Shuvaev VA, Abdulkadyrov KM, Martynkevich IS, Fominykh MS. First Line Treatment Choice for Chronic Myelogenous Leukemia: Modeling of Clinical and Economic Factors.. Clinical oncohematology. 2015;8(1):78–83 (In Russ).


Background. Second generation tyrosine kinase inhibitors (nilotinib and dasatinib) have advantages over imatinib in frequency and rate of cytogenetic and molecular responses obtaining in chronic myelogenous leukemia (CML) treatment. At the same time, they produced more severe adverse effects and are more expensive than imatinib. At present, CML patients with stable deep molecular response are considered as candidates for enrollment into clinical trials studying the management of treatment-free remission. Constant growth of expenses for CML diagnosing and treatment require a pharmacoeconomic analysis in order to optimize expenses and provide cost-effectiveness data for introduction of novel highly effective drugs.

Objective. Pharmacoeconomic modeling of the choice of CML treatment using first and second generation tyrosine kinase inhibitors in first-line therapy with an analysis of sensitivity of clinico-economic factors.

Methods. Pharmacoeconomic modeling of CML diagnosing and treatment. Cost-utility analysis of first and second generation tyrosine kinase inhibitors in first-line treatment. Sensitivity analysis with identification of most important clinical and economic factors affecting treatment results. Simulation for feasibility analysis of the nationwide use of first and second generation tyrosine kinase inhibitors in first-line therapy.

Results. Sensitivity analyses of pharmacoeconomic models showed its robustness. The threshold limits for drug costs and frequency of achievement of a complete molecular response affecting economic feasibility of the choice of first and second generation tyrosine kinase inhibitors were determined.

Conclusions. These pharmacoeconomic models may be applied for improvement of diagnostic and therapeutic standards.

Keywords: chronic myeloleukemia, tyrosine kinase inhibitors, imatinib, nilotinib, dasatinib, pharmacoeconomics, cost-effectiveness.

Received: September 11, 2014

Accepted: November 7, 2014

Read in PDF (RUS)pdficon


  1. Голенков А.К., Высоцкая Л.Л., Трифонова Е.В. Эффективность программы лечения хронического миелолейкоза гливеком в широкой клинической практике. Альманах клинической медицины МОНИКИ. 2008;18:9–13. [Golenkov AK, Vysotskaya LL, Trifonova EV. Effectiveness of treatment regimen for chronic myeloleukemia using Glivec in wide clinical practice. Al’manakh klinicheskoi meditsiny MONIKI. 2008;18:9–13. (In Russ)]
  2. Стахина О.В., Туркина А.Г., Гусарова Г.А. и др. Отдаленные результаты выживаемости больных в поздней хронической фазе Ph+ хронического миелолейкоза при лечении иматиниб мезилатом (Гливек®). Вестник гематологии. 2009;5(2):42. [Stakhina OV, Turkina AG, Gusarova GA, et al. Delayed survival outcomes of patients with late chronic phase of Rh+ chronic myeloleukemia treated with imatinib mesylate (Glivec®). Vestnik gematologii. 2009;5(2):42. (In Russ)]
  3. Шуваев В.А., Абдулкадырова А.С., Мартынкевич И.С. и др. Опыт лечения хронического миелолейкоза в Санкт-Петербурге. Вестник гематологии. 2011;7(1):43. [Shuvaev VA, Abdulkadyrova AS, Martynkevich IS, et al. Experience of treatment of chronic myeloleukosis in Saint Petersburg. Vestnik gematologii. 2011;7(1):43. (In Russ)]
  4. Deininger M, O’Brien SG, Guilhot F, et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Blood (ASH Annual Meeting Abstracts). 2009;114(22):1126.
  5. Cortes JE, Hochhaus A, Kim D-W, et al. Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response. Blood (ASH Annual Meeting Abstracts). 2013;122:653.
  6. Saglio G, Hochhaus A, Hughes TP, et al. ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes. Blood (ASH Annual Meeting Abstracts). 2013;122:92.
  7. National Institute for Health and Care Excellence. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70). April 2012.
  8. Emir H, Albrecht-Schgoer K, Huber K, et al. Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML. Blood. 2013;122(21):257.
  9. Krauth M-T, Herndlhofer S, Schmook M-T, et al. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica. 2011;96(1):163–6. doi: 10.3324/haematol.2010.030494.
  10. Montani D, Bergot E, Gunther S, et al. Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. Circulation. 2012;125(17):2128–37. doi: 10.1161/CIRCULATIONAHA.111.079921.
  11. Quintas-Cardama A, Kantarjian H, O’Brien S, et al. Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure. J Clin Oncol. 2007;25(25):3908–14. doi: 10.1200/jco.2007.12.0329.
  12. Saglio G, Larson R, Hughes TP, et al. Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (Pts) with type 2 diabetes in the ENESTnd trial. Blood (ASH Annual Meeting Abstracts). 2010;116:3430.
  13. Государственный реестр цен на ЖНВЛП (ЖНВЛС) по состоянию на 23 июня 2014 г. [State register of prices for vital and essential medicines as of June 23, 2014.]
  14. Mahon F-X, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35. doi: 10.1016/S1470-2045(10)70233-3.
  15. Rea D, Rousselot P, Nicolini FE, et al. Discontinuation of Dasatinib or Nilotinib in Chronic Myeloid Leukemia (CML) Patients (pts) with Stable Undetectable Bcr-Abl Transcripts: Results From the French CML Group (FILMC). Blood (ASH Annual Meeting Abstracts). 2011;118(21):604.
  16. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease. J Clin Oncol. 2014;32(5):424–30. doi: 10.1200/jco.2012.48.5797.
  17. Takahashi N, Kyo T, Maeda Y, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012;97(6):903–6. doi: 10.3324/haematol.2011.056853.
  18. Shuvaev VA, Abdulkadyrova AS, Martynkevich IS, et al. Bonus free life’s in CML – pharmacoeconomic modeling first and second generation TKIs in first-line CML treatment with therapy cessation. ELN Inform Letter. October 2013:14.
  19. Воробьев А.П. Клинико-экономический анализ. М.: Ньюдиамед, 2008. 777 с. [Vorob’ev AP. Kliniko-ekonomicheskii analiz. (Clinical and economic analysis). Moscow: Newdiamed Publ.; 2008. 777 p. (In Russ)]
  20. Report for Selected Countries and Subjects. World Economic Outlook Database, April 2013. International Monetary Fund; 2013.